Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.

Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion diagnostic testing. We examined 9450 NSCLC real-world patient samples that underwent both CGP and programmed death-ligand 1 (PD-L1) IHC to understand the biomarker landscape in this patient cohort. By assessing National Comprehensive Cancer Network (NCCN)-recommended biomarkers including genomic alterations, tumor mutational burden (≥10 mutations/Mb cut-off), and PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50% cut-off), we show that CGP + PD-L1 IHC yielded potentially actionable results for 70.5% of the 9,450 patients with NSCLC. Among the remaining 29.5% (2,789/9,450) of patients, 86.7% (2,419/2,789) were potentially eligible for another biomarker-associated therapy and/or clinical trial based on their genomic profile. In addition, in the PD-L1

Informations de copyright

Copyright © 2021 Huang, Severson, Haberberger, Duncan, Hemmerich, Edgerly, Ferguson, Frampton, Owens, Williams, Elvin, Vergilio, Killian, Lin, Morley, McEwan, Holmes, Danziger, Cohen, Sathyan, McGregor, Reddy, Venstrom, Anhorn, Alexander, Brown, Ross and Ramkissoon.

Déclaration de conflit d'intérêts

Authors RH, ES, JH, DD, AH, CE, NF, CO, CB, JR, SR, GF, EW, JE, JV, JK, DL, SM, DM, OH, ND, PS, KM, PR, JV, RA, and BA were employed by the company Foundation Medicine, Inc., which is a wholly subsidiary of Roche and receive stock from Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.